Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
The Cannabist Company Holdings operates vertically-integrated cannabis cultivation, processing, and retail dispensary operations across multiple U.S. states including Maryland, Virginia, Colorado, and Pennsylvania. The company faces severe financial distress with negative cash flow, declining revenues (-10.3% YoY), and a distressed balance sheet (current ratio 0.89, negative equity), reflecting intense pricing pressure from state-level oversupply and limited interstate commerce restrictions that prevent geographic diversification benefits.
Generates revenue through state-licensed vertical integration: cultivating cannabis at indoor/greenhouse facilities, processing into finished goods, and selling through owned dispensaries at retail margins (typically 40-60% gross margins in mature markets). Pricing power has eroded significantly due to state-level oversupply in key markets like Colorado and Maryland, compressing wholesale prices 30-50% from 2023 peaks. Competitive advantages include established cultivation licenses (high barriers to entry in limited-license states), retail footprint in strategic locations, and brand recognition in local markets. However, federal illegality prevents interstate commerce, forcing redundant state-by-state infrastructure that limits economies of scale.
Federal cannabis rescheduling progress - potential DEA reclassification from Schedule I to Schedule III would enable 280E tax deduction relief (currently disallowed business expenses add ~40-50% effective tax burden)
State-level pricing stabilization - wholesale flower prices per pound in key markets like Maryland ($800-1200/lb currently vs $2000+ in 2022) and Colorado
Liquidity events and restructuring announcements - given negative cash flow and 0.89 current ratio, any debt refinancing, asset sales, or bankruptcy proceedings
Same-store sales trends at retail dispensaries - traffic and basket size indicating consumer demand resilience amid discretionary spending pressures
New market entry or license awards - expansion into high-growth limited-license states (though capital constraints currently limit this)
Federal prohibition maintains 280E tax burden (disallowing business expense deductions except cost of goods sold), creating 40-50% effective tax rates that make profitability structurally difficult even for well-run operators
State-level oversupply from unlimited cultivation licenses in key markets (Colorado, Oklahoma, Maryland) has created sustained wholesale price deflation, with prices down 50-70% from 2021-2022 peaks and no clear supply rationalization path
Interstate commerce restrictions force inefficient state-by-state vertical integration, preventing economies of scale and requiring duplicative infrastructure that advantages MSOs with deeper capital reserves
Well-capitalized multi-state operators (Curaleaf, Trulieve, Green Thumb) have superior cost structures, brand portfolios, and ability to weather prolonged price compression, potentially forcing distressed asset acquisitions
Illicit market competition remains significant (30-40% of total consumption in mature markets) due to price advantages from avoiding taxes and regulatory costs, limiting total addressable market for legal operators
Retail saturation in mature markets with dispensary density exceeding sustainable levels, driving promotional intensity and margin compression
Immediate liquidity crisis risk - 0.89 current ratio and negative operating cash flow indicate potential inability to meet short-term obligations without additional financing, which may be unavailable or highly dilutive given distressed valuation
Negative shareholder equity and -2.92 debt/equity ratio suggest balance sheet insolvency on a book value basis, with restructuring or bankruptcy as potential outcomes if operations don't stabilize
High-cost debt structure with limited refinancing options due to federal illegality, creating potential covenant violations and forced asset sales at distressed valuations
moderate-to-high - Cannabis retail exhibits discretionary spending characteristics despite medical use cases. During economic downturns, consumers trade down to lower-priced flower from premium concentrates/edibles, and frequency of purchase declines. The -10.3% revenue decline partially reflects weakening consumer spending power amid 2024-2025 inflation. However, cannabis shows some recession resilience compared to other discretionary categories due to habitual consumption patterns and lack of close substitutes.
High interest rate sensitivity through multiple channels: (1) Cannabis companies pay 15-25% interest rates on debt due to federal illegality preventing traditional bank financing, making elevated Fed Funds rate extremely costly; (2) Higher rates reduce consumer discretionary spending power, particularly among younger demographics that over-index in cannabis consumption; (3) Valuation multiples compress as risk-free rates rise, disproportionately affecting unprofitable growth companies. Current negative cash flow makes refinancing risk acute if rates remain elevated.
Severe credit constraints due to federal illegality - cannabis companies cannot access traditional banking, forcing reliance on high-cost private credit (15-25% interest), sale-leasebacks, and dilutive equity. The -2.92 debt/equity ratio and 0.89 current ratio indicate potential covenant violations or restructuring risk. Credit market tightening directly threatens survival for cash-burning operators.
Distressed/special situations investors and high-risk speculators betting on federal reform catalyst or restructuring recovery. The -75.7% six-month return, negative cash flow, and distressed balance sheet have eliminated institutional quality investors. Current holders are likely either trapped legacy investors or opportunistic traders playing technical bounces or policy catalysts. Not suitable for fundamental value or growth investors given lack of profitability path under current regulatory structure.
high - Stock exhibits extreme volatility driven by federal policy headlines (rescheduling rumors, congressional bills), liquidity crises, and low float/market cap amplifying price swings. Cannabis sector beta typically 1.5-2.5x broader market. The -42.4% one-year return with sharp intra-period swings reflects binary outcome risk profile.
